Novel treatment for stroke and myocardial infarction
| Reference number | |
| Coordinator | CERENO SCIENTIFIC AB - GU Holding |
| Funding from Vinnova | SEK 2 000 000 |
| Project duration | May 2013 - February 2016 |
| Status | Completed |
Purpose and goal
The aim of the project was to verify the commercial potential of the development of a new antithrombotic treatment modality for prevention of myocardial infarction and stroke. The ultimate goal was define an optimal business model based on this verification, to be able to take the drug to market and clinical use. This goal has been reached during the course of the project, and we now have a clear and simple business model to use for the future commercial development.
Expected results and effects
The principal result of the completed verification project is that a clear and well structured business model has been developed. Based on this model, we expect that the further commercial development will be facilitated.
Planned approach and implementation
The critical analysis provided by the Vinnova reference group during the course of the project has helped us to evaluate and redefine the original business model. This has added significant value to the project and has reinforced our commercial potential.